Daily Management Review

Crisaborole Related Study Results Have Been Announced By Anacor


10/31/2015


Anacor presents a compilation of all the ‘top line’ study results regarding the Crisaborole ointment involved in curing dermatitis.



Anacor Pharmaceuticals, Inc. came up with “top-line results from the long-term safety study of Crisaborole Topical Ointment”. The said study was being conducted for developing “a novel non-steroidal topical anti-inflammatory phosphodiesterase-4” that would act as an inhibitor which will have the potential of treating “mild-to-moderate atopic dermatitis in children and adults”. The senior vice president cum the chief medical officer at Anacor, Lee Zane commented:
“We are very pleased with the results of this successful study which confirmed the safety profile of crisaborole demonstrated in the Phase 3 pivotal studies when used intermittently for up to 12 months. This study adds significantly to our robust clinical database, which now includes data from over 2,000 subjects treated with crisaborole across its clinical development program.”
 
The ointment Crisaborole was observed to be “well-tolerated”, while also showed a consistent “safety profile” in comparison to the “positive Phase 3 pivotal studies” that were carried out in the month of July 2015. There no reports of “treatment-related serious adverse” issues in the case of Crisaborole. The most serious side effects were noted to be “mild in severity, and transient”. As per StreetInsider.com:
“The most common treatment-related adverse events reported by at least 2% of subjects were atopic dermatitis (3.1%) and application site pain (2.3%)”.
 
One of the “clinical investigators” involved in the multicentre trial, the “Dermatology and Pediatrics” professor at the University of “Texas Health Science Centre” situated at Houston, Adelaide Hebert remarked:
“The safety profile demonstrated by crisaborole when used for the long-term management of mild-to-moderate atopic dermatitis in patients as young as 2 years old could be extremely relevant to prescribing physicians and patients. Atopic dermatitis, or eczema, is a chronic skin condition characterized by recurrent flares. Currently, the most common topical prescription treatments, corticosteroids and calcineurin inhibitors, carry concerns about their long-term safety, so their continuous application for long periods of time is not recommended. If crisaborole is approved, it has the potential to dramatically change how this disease is managed.”
 
While, the chief medical officer and the senior vice president of Anacor, Lee Zane stated:
“We want to thank all of the clinical investigators, patients and their families who participated in this study. With the successful completion of this important study, we now expect to file the NDA in the first quarter of 2016.”




References:
www.streetinsider.com
 







Science & Technology

Complete Computer System For Self Driving Cars Launched By Qualcomm

In A Lifetime We Could Accumulate 20Kg Micro-Plastic In Our Body

Creator Of The First 'Gene-Edited' Babies Of The World Gets 3 Year Jail Term In China

China to deploy giant Beidou global navigation system in 2020

VW Zwickau factory is getting ready for electric cars production

Airbus: Passenger hybrid aircraft to take off before 2035

Ocado To Introduce ‘Mini Robotic Warehouse’ With Standard Productivity

AB InBev’s Piled Up Alcohol Is ‘Too Good to Waste’

Ericsson Mobility forecasts nearly fourfold increase in mobile traffic by 2025

Elon Musk: We received 146,000 orders for Cybertruck

World Politics

World & Politics

Indonesia, UAE sign nearly $23B deal

US to respond to Iran’s attacks on US bases in Iraq

Irish Passport issues hit record in anticipation of Brexit

Reporters Without Borders calls to release Julian Assange

IMF allocates Ecuador $ 500 mln more to support reforms

French pension reform chief to resign

Poland refuses to join EU 2050 climate deal

EU to fight food waste